Safety, tolerability and clinical implementation of ‘ready-to-use’ (68)gallium-DOTA0-Tyr3-octreotide ((68)Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs)

BACKGROUND: (68)Ga-DOTA0-Tyr3-octreotide ((68)Ga-DOTATOC) positron emission tomography–CT (PET-CT) has superior diagnostic performance compared to the licensed tracer OctreoScan single photon emission CT–CT in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs). A new preparation...

Descripción completa

Detalles Bibliográficos
Autores principales: Manoharan, Prakash, Lamarca, Angela, Navalkissoor, Shaunak, Calero, Jose, Chan, Pei San, Julyan, Peter, Sierra, Maribel, Caplin, Martyn, Valle, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078687/
https://www.ncbi.nlm.nih.gov/pubmed/32188715
http://dx.doi.org/10.1136/esmoopen-2019-000650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078687/
https://www.ncbi.nlm.nih.gov/pubmed/32188715
http://dx.doi.org/10.1136/esmoopen-2019-000650

Ejemplares similares